![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Autoimmune Disorders |
Free Subscription
3 Int J Clin Pract |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Autoimmune Disorders is free of charge.
Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A
Systematic Meta-Analysis.
Int J Clin Pract. 2022;2022:4308470.
PubMed
Abstract available
Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe
Proteinuria: A Systematic Review and Network Meta-Analysis.
Int J Clin Pract. 2022;2022:4996239.
PubMed
Abstract available
COVID-19 Vaccination Intention and Vaccine Hesitancy among Patients with
Autoimmune and Autoinflammatory Rheumatological Diseases: A Survey.
Int J Clin Pract. 2022;2022:5931506.
PubMed
Abstract available
Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis
and Pure Red Cell Aplasia After Thymectomy: A Case Report and Literature Review.
Intern Med. 2022 Jun 14. doi: 10.2169/internalmedicine.9743.
PubMed
Abstract available
Overlap of Thrombotic Microangiopathy and Mesangial Proliferative
Glomerulonephritis Caused by Combination Therapy with Atezolizumab and
Bevacizumab.
Intern Med. 2022 Jun 14. doi: 10.2169/internalmedicine.9425.
PubMed
Abstract available
Safety and efficacy of fecal microbiota transplantation for treatment of systemic
lupus erythematosus: An EXPLORER trial.
J Autoimmun. 2022 Jun 8:102844. doi: 10.1016/j.jaut.2022.102844.
PubMed
Abstract available
SM03, an Anti-CD22 Antibody, Converts Cis-to-Trans Ligand Binding of CD22 against
alpha2,6-Linked Sialic Acid Glycans and Immunomodulates Systemic Autoimmune
Diseases.
J Immunol. 2022 Jun 10. pii: jimmunol.2100820. doi: 10.4049/jimmunol.2100820.
PubMed
Abstract available
Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to
"overlap" cases.
J Neuroimmunol. 2022;369:577904.
PubMed
Abstract available
Analysis of risk factors for a poor functional prognosis and relapse in patients
with autoimmune encephalitis.
J Neuroimmunol. 2022;369:577899.
PubMed
Abstract available
Coexisting of anti-Ro52 autoantibodies on anti-MDA5 autoantibodies-positive
dermatomyositis is highly associated with rapidly progressive interstitial lung
disease and mortality risk.
J Rheumatol. 2022 Jun 15. pii: jrheum.220139. doi: 10.3899/jrheum.220139.
PubMed
Abstract available
Body mass index as a predictor of MS activity and progression among participants
in BENEFIT.
Mult Scler. 2022;28:1277-1285.
PubMed
Abstract available
Impact of clinical outcomes and imaging measures on health-related quality of
life in secondary progressive MS.
Mult Scler. 2022;28:1286-1298.
PubMed
Abstract available
Pregnancy in women with MS: Impact on long-term disability accrual in a
nationwide Danish Cohort.
Mult Scler. 2022;28:1239-1247.
PubMed
Abstract available
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving
cladribine tablets: The CLARITY extension study.
Mult Scler. 2022;28:1219-1228.
PubMed
Abstract available
Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica
spectrum disorder: A nationwide cohort study in South Korea.
Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
PubMed
Abstract available
Sclerokeratitis in Granulomatosis with Polyangiitis.
N Engl J Med. 2022;386:2221.
PubMed
Emerging therapies to target CNS pathophysiology in multiple sclerosis.
Nat Rev Neurol. 2022 Jun 13. pii: 10.1038/s41582-022-00675.
PubMed
Abstract available
Optic neuritis: A South African hospital-based prospective study protocol.
PLoS One. 2022;17:e0269514.
PubMed
Abstract available
An evaluation of adverse events following an immunization campaign with the live,
attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
PLoS One. 2022;17:e0269480.
PubMed
Abstract available
Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis
revealed the testable therapeutic target.
Proc Natl Acad Sci U S A. 2022;119:e2123265119.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by